CAR-NKT Immunotherapy Eliminates Endometrial Tumors in Preclinical Models

Researchers at UCLA have developed a new immunotherapy that eliminated tumors in preclinical models of endometrial cancer, offering a potential new approach for patients with cancer that has been difficult to treat and prone to recurrence. The study, published in Experimental Hematology & Oncology, found that CAR-NKT cell therapy outperformed existing immunotherapies in targeting and destroying endometrial cancer cells, particularly in aggressive subtypes.

Endometrial cancer is the most common gynecologic cancer in the United States, and survival rates have declined over recent decades. Aggressive forms such as uterine papillary serous carcinoma represent about 10% of diagnoses but account for nearly 40% of deaths, underscoring the need for new treatment strategies for patients with cancer.

CAR-NKT therapy shows strong tumor elimination in endometrial cancer models

The investigational therapy uses invariant natural killer T cells, known as NKT cells, that are engineered with a chimeric antigen receptor targeting mesothelin, a protein found on endometrial cancer cells. These CAR-NKT cells are designed to detect and destroy tumors through three simultaneous pathways, unlike conventional CAR-T cell therapies that rely on a single recognition mechanism.

In mouse models of endometrial cancer, the therapy achieved complete tumor elimination and prolonged survival. By comparison, conventional CAR-T cells provided only partial and temporary tumor control before the cancer returned. These findings suggest the new approach may address one of the most significant challenges in endometrial cancer care: recurrence, particularly in aggressive disease subtypes.

Additional testing in patient tumor samples and patient-derived tumor cell lines supported these findings. The CAR-NKT therapy demonstrated stronger cancer-killing activity than current immunotherapy approaches, including in difficult-to-treat forms such as uterine papillary serous carcinoma.

Researchers noted that the therapy’s ability to target cancer through multiple pathways may help limit the tumor’s ability to adapt and evade treatment.

Off-the-shelf immunotherapy platform may improve access and cost

The CAR-NKT therapy remains in the preclinical stage and has not yet been tested in humans. All findings reported in the study are based on laboratory models and patient-derived tumor samples.

Unlike personalized immunotherapies that require collecting and modifying a patient’s own immune cells, this approach uses an off-the-shelf platform. CAR-NKT cells are produced from donated blood stem cells in a scalable manufacturing process. Because NKT cells are naturally compatible with different immune systems, a single donation can generate enough cells for thousands of treatments.

This production model may help address key barriers associated with current immunotherapies, including long manufacturing times and high costs. Existing personalized treatments can take weeks to produce and cost hundreds of thousands of dollars. In contrast, CAR-NKT cells can be pre-made, cryopreserved and available when needed, which may improve access for patients with cancer.

The therapy may also have broader applications beyond endometrial cancer. Mesothelin, the protein targeted by the engineered cells, is expressed in several other cancers, including ovarian, breast, pancreatic and lung cancers. As a result, the same product could potentially be used across multiple tumor types without requiring patient-specific customization.

Researchers have completed preclinical studies and are preparing to submit applications to the U.S. Food and Drug Administration to begin clinical trials.

CAR-NKT therapy demonstrates favorable safety profile in preclinical testing

In preclinical testing, the CAR-NKT therapy demonstrated a favorable safety profile. Notably, the engineered cells did not trigger graft-versus-host disease, a serious condition in which donor immune cells attack healthy tissues.

This finding is important for therapies derived from donor cells, as immune-related side effects are a key concern in immunotherapy development. The absence of this complication in preclinical models suggests the therapy may avoid some risks associated with other treatments, though this must be confirmed in human studies.

Researchers also reported no additional safety concerns in their laboratory studies. However, because the therapy has not yet been evaluated in clinical trials, its safety and effectiveness in patients with cancer remain unknown.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

References

1. “Universal, ready-to-use immunotherapy detects and destroys endometrial cancer” News Release. UCLA. March 16, 2026.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.